|
Accueil > Actualité
AstraZeneca: Enhertu approval extended in US
(CercleFinance.com) - AstraZeneca announced on Monday that it has won approval from the US FDA to market its Enhertu immunotherapy for the treatment of metastatic breast cancer known as "weak HER2".
The antibody - developed and marketed with Japan's Daiichi Sankyo - is now approved in the US for the treatment of adult patients with non-operable or metastatic breast cancer that under-expresses the HER2 gene. This approval is for individuals who have received prior chemotherapy or have experienced disease relapse within six months of completing treatment. Enhertu - a conjugate that targets HER2 receptors - is already approved in about 30 countries for the treatment of adult patients with HER2-positive breast cancer. The drug is also approved in some countries for the treatment of certain gastric cancers that also express the HER2 gene. Copyright (c) 2022 CercleFinance.com. All rights reserved. |
19/04/2024 16:35
TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables 19/04/2024 15:53 L'Oréalentouré après ses ventes trimestrielles 19/04/2024 15:45 Nissanrévision à la baisse des prévisions sur l'exercice Tous les articles sociétés |
